HomeCompareCLVSF vs ORCC

CLVSF vs ORCC: Dividend Comparison 2026

CLVSF yields 1.63% · ORCC yields 9.79%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CLVSF wins by $632.00 in total portfolio value· pulled ahead in Year 7
10 years
CLVSF
CLVSF
● Live price
1.63%
Share price
$16.14
Annual div
$0.26
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$22.0K
Annual income
$180.86
Full CLVSF calculator →
ORCC
ORCC
● Live price
9.79%
Share price
$13.48
Annual div
$1.32
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.4K
Annual income
$1.04
Full ORCC calculator →

Portfolio growth — CLVSF vs ORCC

📍 CLVSF pulled ahead of the other in Year 7

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCLVSFORCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CLVSF + ORCC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CLVSF pays
ORCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CLVSF
Annual income on $10K today (after 15% tax)
$138.35/yr
After 10yr DRIP, annual income (after tax)
$153.73/yr
ORCC
Annual income on $10K today (after 15% tax)
$832.34/yr
After 10yr DRIP, annual income (after tax)
$0.88/yr
At 15% tax rate, CLVSF beats the other by $152.85/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CLVSF + ORCC for your $10,000?

CLVSF: 50%ORCC: 50%
100% ORCC50/50100% CLVSF
Portfolio after 10yr
$21.7K
Annual income
$90.95/yr
Blended yield
0.42%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ORCC right now

CLVSF
Analyst Ratings
1
Hold
Consensus: Hold
Altman Z
12.3
Piotroski
6/9
ORCC
Analyst Ratings
9
Buy
4
Hold
1
Sell
Consensus: Buy
Price Target
$16.00
+18.7% upside vs current
Range: $16.00 — $16.00
Altman Z
0.5
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CLVSF buys
0
ORCC buys
18
PoliticianChamberTickerTypeAmountDate
Trey Hollingsworth🏢 House$ORCC▲ Buy$15,001 - $50,0002022-06-23
Trey Hollingsworth🏢 House$ORCC▲ Buy$250,001 - $500,0002022-06-16
Trey Hollingsworth🏢 House$ORCC▲ Buy$15,001 - $50,0002022-06-14
Trey Hollingsworth🏢 House$ORCC▲ Buy$50,001 - $100,0002022-06-13
Trey Hollingsworth🏢 House$ORCC▲ Buy$50,001 - $100,0002022-06-10
Trey Hollingsworth🏢 House$ORCC▲ Buy$15,001 - $50,0002022-06-09
Trey Hollingsworth🏢 House$ORCC▲ Buy$15,001 - $50,0002022-06-08
Trey Hollingsworth🏢 House$ORCC▲ Buy$50,001 - $100,0002022-06-03
Trey Hollingsworth🏢 House$ORCC▲ Buy$15,001 - $50,0002022-05-24
Trey Hollingsworth🏢 House$ORCC▲ Buy$100,001 - $250,0002022-05-20
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCLVSFORCC
Forward yield1.63%9.79%
Annual dividend / share$0.26$1.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%-50%
Portfolio after 10y$22.0K$21.4K
Annual income after 10y$180.86$1.04
Total dividends collected$1.7K$1.0K
Payment frequencyquarterlyquarterly
SectorStockBDC
Analyst consensusHoldBuy

Year-by-year: CLVSF vs ORCC ($10,000, DRIP)

YearCLVSF PortfolioCLVSF Income/yrORCC PortfolioORCC Income/yrGap
1$10,863$162.76$11,190$489.61$327.00ORCC
2$11,788$165.24$12,229$256.01$441.00ORCC
3$12,781$167.59$13,216$130.74$435.00ORCC
4$13,846$169.82$14,207$66.02$361.00ORCC
5$14,987$171.92$15,234$33.17$247.00ORCC
6$16,210$173.92$16,317$16.62$107.00ORCC
7← crossover$17,520$175.81$17,468$8.32+$52.00CLVSF
8$18,924$177.59$18,695$4.16+$229.00CLVSF
9$20,428$179.27$20,006$2.08+$422.00CLVSF
10$22,039$180.86$21,407$1.04+$632.00CLVSF

CLVSF vs ORCC: Complete Analysis 2026

CLVSFStock

CellaVision AB (publ) develops and sells digital solutions for blood and body fluids analysis in health care services sector in Sweden, Europe, the Middle East, Africa, the Americas, and the Asia Pacific. The company provides CellaVision DM1200 and CellaVision DM9600, which automatically capture digital images of cells from blood smears and body fluid preparations; and CellaVision DC-1, an analyzer. It also offers CellaVision Peripheral Blood Application that enables laboratories to automate, standardize, and simplify morphological examination of peripheral blood smears; CellaVision Advanced RBC Application, which enables to perform comprehensive examination of red blood cell morphology; CellaVision Body Fluid Application that enables laboratories to automate, standardize, and simplify morphological examination of body fluid preparations; and CellaVision Remote Review Software, which removes restrictive geographical constraints from the smear review process. In addition, the company provides CellaVision Server Software that creates a single streamlined workflow within one or multiple testing sites; CellaVision Dashboard, a tool designed to give an at-a-glance view of CellaVision analyzer and reviewer metrics; CellaVision Proficiency Software, a cloud-based software designed to help laboratory managers assess, monitor, and promote staff competency in the area of cell morphology; CellaVision CellAtlas, which combines a series of mini lectures with an extensive cell image library; and CellaVision VET that offers digital solutions for medical microscopy in the field of hematology. It sells its products to hospital and commercial laboratories. CellaVision AB (publ) was incorporated in 1994 and is headquartered in Lund, Sweden.

Full CLVSF Calculator →

ORCCBDC

Owl Rock Capital Corporation is a business development company. The fund makes investments in senior secured or unsecured loans, subordinated loans or mezzanine loans and also considers equity-related securities including warrants and preferred stocks also pursues preferred equity investments and common equity investments. Within private equity, it seeks to invest in growth, acquisitions, market or product expansion, refinancings and recapitalizations. It seeks to invest in middle market companies based in the United States, with EBITDA between $10 million and $250 million annually and/or annual revenue of $50 million and $2.5 billion at the time of investment.

Full ORCC Calculator →
📬

Get this CLVSF vs ORCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CLVSF vs SCHDCLVSF vs JEPICLVSF vs OCLVSF vs KOCLVSF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.